About H-Immune
H-Immune is a company based in Paris (France) founded in 2016 was acquired by HiFiBiO in October 2018. H-Immune operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Revolution Medicines, among others.
- Headquarter Paris, France
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of H-Immune
Detailed funding history for H-Immune
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in H-Immune
H-Immune has secured backing from 1 investor. Prominent investors backing the company include HiFiBiO.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Antibody-based drugs are discovered using a specialized technology platform.
|
Locked | Locked | Locked |
Investor details for H-Immune
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by H-Immune
Investment portfolio details for H-Immune
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - H-Immune
Detailed financials for H-Immune
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
H-Immune Comparisons
Peer comparison for H-Immune
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of H-Immune
H-Immune operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Revolution Medicines, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
Detailed competitors of H-Immune
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on H-Immune
Complete news archive for H-Immune
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about H-Immune
H-Immune was founded in 2016.
H-Immune is headquartered in Paris, France.
H-Immune SAS was founded in 2016 as a spin-out from the French Atomic Energy Commission and is headquartered in Paris, France. Operations focus on the immuno-oncology sector within biotechnology, where proprietary In Vitro Immunization (IVI) technology is employed to produce fully human monoclonal antibodies targeting various cancer therapies. Affinity maturation by B lymphocytes is leveraged in this process. A strategic research partnership with Pierre Fabre was established in March 2017.
H-Immune's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
H-Immune has 1 investor. Key investors include HiFiBiO.